Efficacy and Safety of Vildagliptin in Type 2 Diabetes
Not Applicable
Completed
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2022/01/039112
- Lead Sponsor
- Cipla Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1691
Inclusion Criteria
all patients treated with metformin XR on total daily dose of at least 1000 mg
Exclusion Criteria
those with hypersensitivity reactions pregnancy lactation or other contraindications for use of vildagliptin
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measure is Change in Glycated haemoglobin HbA1c from baseline to end of 3 monthsTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method efficacy and tolerability evaluatedTimepoint: 3 months